BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 16, 2025
Home » Authors » Mark McCarty

Articles by Mark McCarty

Entellus launches new sinus surgery unit with more reach

May 3, 2010
By Mark McCarty

Market Developments: CMS to cover NaF-18 PET for metastatic bone cancer under CED

May 1, 2010
By Mark McCarty

Washington roundup: CDRH revamps advisory panel voting, discussion procedures

April 29, 2010
By Mark McCarty

Schultz upbeat about devices but venture capitalist worried

April 27, 2010
By Mark McCarty

Shuren: systemic changes may at times trump immediate needs

April 26, 2010
By Mark McCarty
WASHINGTON – Jeff Shuren, the new director of the Center for Devices and Radiological Health has made extensive time in his schedule for communicating with industry, and this year's annual conference by the Food and Drug Law Institute (FDLI; Washington) served as yet another forum for the new device chief. He reviewed a number of issues raised by device makers since he took the job, but one comment he made may suggest something about why industry sees the center as less responsive. Shuren informed the audience that while agency employees are instructed to respond promptly to industry inquiries, other issues may supersede this and other short-term priorities. (Medical Device Daily)
Read More

Tyler advising FDA to fill in statutory voids aggressively

April 23, 2010
By Mark McCarty
WASHINGTON – FDA Commissioner Margaret Hamburg, MD, opened the plenary session on the first day of the 53rd Annual FDLI Conference, hosted by the Food and Drug Law Institute (FDLI; Washington), and she made it clear at the outset that the agency will not hesitate to ask Congress for additional statutory authority should she conclude that such a request would be appropriate. On the other hand, the agency's new chief counsel, Ralph Tyler, also made a point very clear, that his office would do its best to facilitate enforcement action even in the absence of direct statutory authority, assuming that the intended action does not explicitly run afoul of the statute. (Medical Device Daily)
Read More

Washington roundup: FDA announces initiative for medical devices for home use

April 22, 2010
By Mark McCarty

Washington roundup: Clawbacks offset updates for long-term, acute care hospitals

April 21, 2010
By Mark McCarty

Washington roundup: AHRQ says infections acquired in hospitals are still an issue

April 19, 2010
By Mark McCarty

Washington roundup: Journal article says ICD use in older patients needs study

April 16, 2010
By Mark McCarty
Previous 1 2 … 483 484 485 486 487 488 489 490 491 … 575 576 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 16, 2025.
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • Neutrophils in the bloodstream

    Neutrophils put the brakes on fat loss

    BioWorld Science
    Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...
  • PET imaging

    Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints

    BioWorld
    Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing